Originally published at www.seclive.com
Filing in Focus: Cryo-Cell 10-K, February 28, 2014
Cryo-Cell International, Inc. (OTCPK:CCEL) announced its financial results for the full 2013 fiscal year, reporting revenue and earnings growth from last year. The company, which is the first private cord blood bank in the world that separates and stores stem cells, posted steady annual revenue growth of $19.0M, up from $18.0M a year ago. The majority of its revenue is from processing and storage, accounting for $17.7M, with the remaining $1.3M from licensee income. Compared to the year prior, processing and storage revenue was $16.6M with $1.4M in licensee income. The company posted earnings of $27K and $0.00 per share, up from the $6.3M net loss and $0.56 loss per share in 2012. Co-CEO Mark Portnoy commented that the company's revenue increase shows it is headed in the right direction.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.